Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARK Genomic Revolution ETF (NY: ARKG )

23.61 -0.85 (-3.48%)
Official Closing Price Updated: 8:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ARK Genomic Revolution ETF

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
Exposures Layoff
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
Via Talk Markets
Topics ETFs Stocks / Equities
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
On Friday, Cathie Wood-led Ark Invest made significant trades involving PLTR, ARKB, and QSI. The PLTR trade sold shares worth $1.6 million, aligning with Ark's trend of reducing their position in the... 
Via Benzinga
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
On Wednesday Dec. 11, 2024, Cathie Wood-led Ark Invest sold $21.8 million worth of Tesla shares. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. as a cornerstone of technological innovation... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Momentum Model For Trading SMID Biotech Stocks: Broad Rally Underway
Biotech stocks are poised for a recovery in a seasonally strong period through January 2025. 
Via Talk Markets
Topics ETFs Stocks / Equities
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3... 
Via Benzinga
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
On Wednesday, Ark Invest, led by Cathie Wood, made significant trades in Moderna Inc. (NASDAQ:MRNA) and Square Inc. (NYSE:SQ). The Moderna Trade 
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
On Wednesday, Cathie Wood’s Ark Invest made significant trades involving Block Inc (NYSE:SQ) and Moderna Inc (NASDAQ:MRNA). The SQ Trade 
Via Benzinga
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
On Thursday Oct 10, 2024 Cathie Wood-Led Ark Invest sold over $9 million worth of Moderna stock. 
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
Almost Every Ark Fund Is Now Underperforming The Overall Market. Here's Why.
The fund company focuses on the right industries, but these industries' stocks require a very particular economic backdrop and market environment. 
Via The Motley Fool
5 Technology ETFs At The Forefront Of The August Rebound
Here are five technology ETFs that have been leading the way higher over the past week. 
Via Talk Markets
Topics ETFs
Cathie Wood Buys $28 Million Of Amazon, Targets Crypto; Sells $26 Million Of This Stock
Cathie Wood bought the dip on Amazon stock, Coinbase, Robinhood, Meta and more. ARK Invest unloaded on tech names. 
Via Investor's Business Daily
Cathie Wood-Led Ark Invest Went Shopping For AMD, Tesla, Amazon, Coinbase, Robinhood, Meta And Palantir Shares Amid Market Crash On Monday
Via Benzinga
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark reposed its faith in the company. 
Via Benzinga
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF, despite its recent underperformance. 
Via Benzinga
Topics ETFs
Why Ginkgo Bioworks Stock Is Sinking Today
There was double trouble for this beaten-down biotech stock. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
Here's How Cathie Wood (Almost) Completely Missed the Boat on Artificial Intelligence (AI) -- and the Simplest Way You Can Avoid Making the Same Mistake
The tide has gone out on ARK Invest's ETFs, and it doesn't look pretty. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Cathie Wood Has Been Steadily Selling Shares of This Growth Stock. Should You?
Teladoc's share performance has reflected its earnings struggles... 
Via The Motley Fool
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir 
Via Benzinga
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
You don't need to buy her picks, but it's worth understanding them. 
Via The Motley Fool
Cathie Wood's Ark Invest Scoops Up Shares Of AMD And Palantir — Dumps Moderna Stock Worth $4.4M
Via Benzinga
Investment Advisor Says 'Throwing Random Darts At Tickers' Would Beat ARKK As Cathie Wood's Flagship Fund Lags Far Behind Soaring Market: 'How Do They Do It?!'
Ram Ahluwalia of Lumida Wealth pointed to Ark's flagship ETF trading over 70% below its all-time high amid the S&P 500's recent record highs. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update
As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on the trend. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.